Global Nocturia Supply, Demand and Key Producers, 2026-2032
Description
The global Nocturia market size is expected to reach $ 4358 million by 2032, rising at a market growth of 4.9% CAGR during the forecast period (2026-2032).
Nocturia, also known as nocturnal polyuria, is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. The three broad categories of nocturia are mixed nocturia, bladder storage problems, and nocturnal polyuria.
The global nocturia market, focused on the treatment of nighttime urination, is growing due to an increasing aging population, rising awareness of urinary disorders, and advancements in treatment options. Below are some key trends driving the market:
1. Growing Aging Population
Primary Driver: Nocturia is more prevalent among the elderly, and with a rapidly aging global population, the demand for nocturia treatments is rising. Regions with older populations, such as Europe, North America, and Japan, are seeing increased incidence rates.
Impact: The increase in elderly individuals with nocturia-related issues is expected to drive the demand for pharmaceutical treatments and non-pharmaceutical interventions.
2. Advancements in Treatment Options
Medications: A range of medications, including anticholinergics, desmopressin, and beta-3 adrenergic receptor agonists, are commonly used to treat nocturia. New drug formulations are being developed to reduce side effects and improve efficacy.
Emerging Therapies: Research into gene therapies and targeted molecular therapies is advancing. Additionally, the combination of medications for better symptom control is being explored.
Non-Pharmacological Treatments: Beyond drugs, lifestyle interventions, such as fluid management, bladder training, and devices like bedwetting alarms, are gaining attention as complementary treatments.
3. Increasing Awareness and Diagnosis
Education: Public health campaigns and awareness programs about nocturia are encouraging individuals to seek medical help. Increased awareness is expected to drive the market as more people seek treatment for the condition.
Early Diagnosis: Enhanced diagnostic tools, including better urodynamic testing and digital health platforms for symptom tracking, are improving early detection and management of nocturia.
4. Regional Growth
North America: The U.S. holds the largest market share due to its advanced healthcare infrastructure, higher awareness, and the presence of major pharmaceutical companies. Increasing cases of nocturia among older adults are a significant market driver.
Europe: Aging populations, particularly in Western Europe, are contributing to the increased demand for nocturia treatments. The market in this region benefits from well-established healthcare systems.
Asia-Pacific: The growing healthcare infrastructure in countries like China, Japan, and India is expected to boost market growth. Rising healthcare expenditure and increasing elderly populations in these regions are key factors.
Global core nocturia manufactures include Astellas Pharma, Allergan, Eli Lilly etc. The top 2 companies hold a share about 30%. North America is the largest market, with a share about 40%, followed by Europe and Asia Pacific with the share about 34% and 18%. In terms of product, alpha blockers is the largest segment, with a share over 37%.
This report studies the global Nocturia demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nocturia, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nocturia that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nocturia total market, 2021-2032, (USD Million)
Global Nocturia total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Nocturia total market, key domestic companies, and share, (USD Million)
Global Nocturia revenue by player, revenue and market share 2021-2026, (USD Million)
Global Nocturia total market by Type, CAGR, 2021-2032, (USD Million)
Global Nocturia total market by Sale Channels, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Nocturia market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharma, Allergan, Ferring Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Sanofi, Pfizer, Abbott, Teva, Mylan, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Nocturia market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Sale Channels. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Nocturia Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Nocturia Market, Segmentation by Type:
Desmopressin
Anticholinergic Drugs
Alpha Blockers
Diuretics
Others
Global Nocturia Market, Segmentation by Underlying Cause:
For Nocturnal Polyuria
For Overactive Bladder
For Prostate-related Nocturia
Others
Global Nocturia Market, Segmentation by Drug Category:
Hormonal Drugs
Urological Functional Agents
BPH Symptom Therapies
Diuretics
Others
Global Nocturia Market, Segmentation by Sale Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies Profiled:
Astellas Pharma
Allergan
Ferring Pharmaceuticals
Eli Lilly
GlaxoSmithKline
Sanofi
Pfizer
Abbott
Teva
Mylan
Novartis
Johnson & Johnson
Merck
Astra Zeneca
Bristol-Myers Squibb
Hainan Zhonghe Pharmaceutical
Fosun Pharma
Hybio Pharmaceutical
Rechon Life Science AB
Zhejiang Conba Pharmaceutical
Chengdu Leer Pharmaceutical
Nanjing Xingyin Pharmaceutical Group
Sun Pharmaceutical Industries Ltd.
APOTEX INC
Sagent Pharmaceuticals
Key Questions Answered
1. How big is the global Nocturia market?
2. What is the demand of the global Nocturia market?
3. What is the year over year growth of the global Nocturia market?
4. What is the total value of the global Nocturia market?
5. Who are the Major Players in the global Nocturia market?
6. What are the growth factors driving the market demand?
Nocturia, also known as nocturnal polyuria, is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. The three broad categories of nocturia are mixed nocturia, bladder storage problems, and nocturnal polyuria.
The global nocturia market, focused on the treatment of nighttime urination, is growing due to an increasing aging population, rising awareness of urinary disorders, and advancements in treatment options. Below are some key trends driving the market:
1. Growing Aging Population
Primary Driver: Nocturia is more prevalent among the elderly, and with a rapidly aging global population, the demand for nocturia treatments is rising. Regions with older populations, such as Europe, North America, and Japan, are seeing increased incidence rates.
Impact: The increase in elderly individuals with nocturia-related issues is expected to drive the demand for pharmaceutical treatments and non-pharmaceutical interventions.
2. Advancements in Treatment Options
Medications: A range of medications, including anticholinergics, desmopressin, and beta-3 adrenergic receptor agonists, are commonly used to treat nocturia. New drug formulations are being developed to reduce side effects and improve efficacy.
Emerging Therapies: Research into gene therapies and targeted molecular therapies is advancing. Additionally, the combination of medications for better symptom control is being explored.
Non-Pharmacological Treatments: Beyond drugs, lifestyle interventions, such as fluid management, bladder training, and devices like bedwetting alarms, are gaining attention as complementary treatments.
3. Increasing Awareness and Diagnosis
Education: Public health campaigns and awareness programs about nocturia are encouraging individuals to seek medical help. Increased awareness is expected to drive the market as more people seek treatment for the condition.
Early Diagnosis: Enhanced diagnostic tools, including better urodynamic testing and digital health platforms for symptom tracking, are improving early detection and management of nocturia.
4. Regional Growth
North America: The U.S. holds the largest market share due to its advanced healthcare infrastructure, higher awareness, and the presence of major pharmaceutical companies. Increasing cases of nocturia among older adults are a significant market driver.
Europe: Aging populations, particularly in Western Europe, are contributing to the increased demand for nocturia treatments. The market in this region benefits from well-established healthcare systems.
Asia-Pacific: The growing healthcare infrastructure in countries like China, Japan, and India is expected to boost market growth. Rising healthcare expenditure and increasing elderly populations in these regions are key factors.
Global core nocturia manufactures include Astellas Pharma, Allergan, Eli Lilly etc. The top 2 companies hold a share about 30%. North America is the largest market, with a share about 40%, followed by Europe and Asia Pacific with the share about 34% and 18%. In terms of product, alpha blockers is the largest segment, with a share over 37%.
This report studies the global Nocturia demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nocturia, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nocturia that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nocturia total market, 2021-2032, (USD Million)
Global Nocturia total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Nocturia total market, key domestic companies, and share, (USD Million)
Global Nocturia revenue by player, revenue and market share 2021-2026, (USD Million)
Global Nocturia total market by Type, CAGR, 2021-2032, (USD Million)
Global Nocturia total market by Sale Channels, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Nocturia market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharma, Allergan, Ferring Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Sanofi, Pfizer, Abbott, Teva, Mylan, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Nocturia market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Sale Channels. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Nocturia Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Nocturia Market, Segmentation by Type:
Desmopressin
Anticholinergic Drugs
Alpha Blockers
Diuretics
Others
Global Nocturia Market, Segmentation by Underlying Cause:
For Nocturnal Polyuria
For Overactive Bladder
For Prostate-related Nocturia
Others
Global Nocturia Market, Segmentation by Drug Category:
Hormonal Drugs
Urological Functional Agents
BPH Symptom Therapies
Diuretics
Others
Global Nocturia Market, Segmentation by Sale Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies Profiled:
Astellas Pharma
Allergan
Ferring Pharmaceuticals
Eli Lilly
GlaxoSmithKline
Sanofi
Pfizer
Abbott
Teva
Mylan
Novartis
Johnson & Johnson
Merck
Astra Zeneca
Bristol-Myers Squibb
Hainan Zhonghe Pharmaceutical
Fosun Pharma
Hybio Pharmaceutical
Rechon Life Science AB
Zhejiang Conba Pharmaceutical
Chengdu Leer Pharmaceutical
Nanjing Xingyin Pharmaceutical Group
Sun Pharmaceutical Industries Ltd.
APOTEX INC
Sagent Pharmaceuticals
Key Questions Answered
1. How big is the global Nocturia market?
2. What is the demand of the global Nocturia market?
3. What is the year over year growth of the global Nocturia market?
4. What is the total value of the global Nocturia market?
5. Who are the Major Players in the global Nocturia market?
6. What are the growth factors driving the market demand?
Table of Contents
158 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Nocturia Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Underlying Cause
- 7 Market Analysis by Drug Category
- 8 Market Analysis by Sale Channels
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
